Cargando…
Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
Forde et al.(1) reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381414/ https://www.ncbi.nlm.nih.gov/pubmed/35858590 http://dx.doi.org/10.1016/j.xcrm.2022.100691 |
| _version_ | 1784769074035687424 |
|---|---|
| author | Leal, Ticiana A. Ramalingam, Suresh S. |
| author_facet | Leal, Ticiana A. Ramalingam, Suresh S. |
| author_sort | Leal, Ticiana A. |
| collection | PubMed |
| description | Forde et al.(1) reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC). |
| format | Online Article Text |
| id | pubmed-9381414 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93814142022-08-18 Neoadjuvant therapy gains FDA approval in non-small cell lung cancer Leal, Ticiana A. Ramalingam, Suresh S. Cell Rep Med Spotlight Forde et al.(1) reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC). Elsevier 2022-07-19 /pmc/articles/PMC9381414/ /pubmed/35858590 http://dx.doi.org/10.1016/j.xcrm.2022.100691 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Spotlight Leal, Ticiana A. Ramalingam, Suresh S. Neoadjuvant therapy gains FDA approval in non-small cell lung cancer |
| title | Neoadjuvant therapy gains FDA approval in non-small cell lung cancer |
| title_full | Neoadjuvant therapy gains FDA approval in non-small cell lung cancer |
| title_fullStr | Neoadjuvant therapy gains FDA approval in non-small cell lung cancer |
| title_full_unstemmed | Neoadjuvant therapy gains FDA approval in non-small cell lung cancer |
| title_short | Neoadjuvant therapy gains FDA approval in non-small cell lung cancer |
| title_sort | neoadjuvant therapy gains fda approval in non-small cell lung cancer |
| topic | Spotlight |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381414/ https://www.ncbi.nlm.nih.gov/pubmed/35858590 http://dx.doi.org/10.1016/j.xcrm.2022.100691 |
| work_keys_str_mv | AT lealticianaa neoadjuvanttherapygainsfdaapprovalinnonsmallcelllungcancer AT ramalingamsureshs neoadjuvanttherapygainsfdaapprovalinnonsmallcelllungcancer |